SCHEMBL20103380

SCHEMBL20103380

CCC1CCC(c2cc(OC)ccc2Cl)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
OPRL1 P41146 4/20 0.39
HTR1A P08908 2/20 0.38
ADRB2 P07550 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
HRH1 P35367 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38
HTR2B P41595 1/20 0.38
HTR5A P47898 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20103368 0.87 PTGDR2 (0.41) GPR84MAPTPTGDR2FFAR4OPRL1
SCHEMBL23216460 0.82 PTGDR2 (0.47) GPR84MEN1KMT2APTGDR2
SCHEMBL12924594 0.80 SIGMAR1 (0.37) FFAR4HTR1ASIGMAR1SLC6A4
SCHEMBL11141713 0.74 SLC6A4 (0.52) MEN1NPC1MAPTRAB9AKMT2A
SCHEMBL11141707 0.74 SLC6A4 (0.52) MEN1NPC1MAPTRAB9AKMT2A
SCHEMBL10017476 0.74 DRD2 (0.57) MAPTSLC6A2HTR2CSLC6A3SLC6A4
SCHEMBL30888638 0.73 PTGDR2 (0.45) MEN1KMT2APTGDR2HTR2COPRM1
SCHEMBL17731175 0.72 FFAR4 (0.42) MEN1NPC1MAPTRAB9AKMT2A
SCHEMBL26793826 0.72 PTGDR2 (0.47) MEN1KMT2APTGDR2
SCHEMBL28710470 0.72 TAS1R3 (0.39) MEN1KMT2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed